Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection
By
Jeffrey Seow,
Carl Graham,
Blair Merrick,
Sam Acors,
Kathryn JA Steel,
Oliver Hemmings,
Aoife O'Bryne,
Neophytos Kouphou,
Suzanne Pickering,
Rui Galao,
Gilberto Betancor,
Harry D. Wilson,
Adrian W. Signell,
Helena Winstone,
Claire Kerridge,
Nigel Temperton,
Luke Snell,
Karen Bisnauthsing,
Amelia Moore,
Adrian Green,
Lauren Martinez,
Brielle Stokes,
Johanna Honey,
Alba Izquierdo-Barras,
Gill Arbane,
Amita Patel,
Lorcan OConnell,
Geraldine O Hara,
Eithne MacMahon,
Sam Douthwaite,
Gaia Nebbia,
Rahul Batra,
Rocio Martinez-Nunez,
Jonathan D Edgeworth,
Stuart JD Neil,
Michael H Malim,
Katie Doores
Posted 11 Jul 2020
medRxiv DOI: 10.1101/2020.07.09.20148429
Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ab responses will be maintained or whether they will provide protection from re-infection. Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the magnitude of the nAb response is dependent upon the disease severity, but this does not affect the kinetics of the nAb response. Declining nAb titres were observed during the follow up period. Whilst some individuals with high peak ID50 (>10,000) maintained titres >1,000 at >60 days POS, some with lower peak ID50 had titres approaching baseline within the follow up period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from Guy's and St Thomas' Hospitals. We suggest that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds. This study has important implications when considering widespread serological testing, Ab protection against re-infection with SARS-CoV-2 and the durability of vaccine protection.
Download data
- Downloaded 87,603 times
- Download rankings, all-time:
- Site-wide: 50
- In infectious diseases: 18
- Year to date:
- Site-wide: 180
- Since beginning of last month:
- Site-wide: 180
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!